Tri Locum Partners LP
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$506.1M2026 Q3
Positions18
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.80.1%
What Changed This Quarter?
Top Holdings
VRTX
Vertex Pharmaceuticals Inc
13.7%
LLY
Eli Lilly
11.7%
TEVA
Teva Pharmaceutical Industries
9.6%
AMRX
Amneal Pharmaceuticals
9.3%
DXCM
Dexcom
8.3%
JAZZ
Jazz Pharmaceuticals
7.3%
ARGX
Argenx
5.8%
ASND
Ascendis Pharma A/S
5.3%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.